Literature DB >> 31140043

Plasticity of left ventricular function with cardiac resynchronization therapy.

Hong-Xia Niu1, Yi-Ran Hu1, Wei Hua2, Min Gu1, Jing Wang1, Michael R Gold3, Shu Zhang1.   

Abstract

PURPOSE: To evaluate the clinical and echocardiographic effects of prolonged cessation and resumption of left ventricular pacing among patients with chronic cardiac resynchronization therapy (CRT).
METHODS: This was a retrospective analysis of patients with long-term CRT who had loss of left ventricular pacing because of battery depletion. Clinical assessment and echocardiographic data were analyzed with comparisons between implant, chronic CRT, loss of CRT, and after resumption of CRT.
RESULTS: There were 7 CRT responders who underwent 8 successful pulse generator replacements due to loss of CRT 6.3 ± 2.3 months after reaching elective replacement interval. With initial CRT implantation, QRS duration decreased from 171 ± 25 to 145 ± 28 ms (P < 0.001) and left ventricular ejection fraction increased from 27.6 ± 8.1 to 53.9 ± 9.6% (P < 0.001). At pulse generator replacement, worsening heart failure was present 6 of 7 patients with significant deterioration of left ventricular function and the left ventricular ejection fraction decreased to 43.4 ± 8.4%(P = 0.001). After resumption of CRT, clinical status and cardiac function recovered with left ventricular ejection fraction increasing to 53.7 ± 8.7% (P = 0.001).
CONCLUSIONS: Prolonged loss of CRT is associated with significant deterioration of left ventricular function and functional status that is fully reversible with resumption of left ventricular pacing.

Entities:  

Keywords:  Battery depletion; Cardiac resynchronization therapy; Heart failure; Loss; Resumption

Mesh:

Year:  2019        PMID: 31140043     DOI: 10.1007/s10840-019-00562-7

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  15 in total

1.  Cardiac resynchronization in chronic heart failure.

Authors:  William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

2.  Mid-term clinical and echocardiographic evaluation of super responders with and without pacing: the preliminary results of a prospective, randomized, single-centre study.

Authors:  Serkan Cay; Ozcan Ozeke; Firat Ozcan; Dursun Aras; Serkan Topaloglu
Journal:  Europace       Date:  2015-05-27       Impact factor: 5.214

3.  2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management.

Authors:  Jean-Claude Daubert; Leslie Saxon; Philip B Adamson; Angelo Auricchio; Ronald D Berger; John F Beshai; Ole Breithard; Michele Brignole; John Cleland; David B Delurgio; Kenneth Dickstein; Derek V Exner; Michael Gold; Richard A Grimm; David L Hayes; Carsten Israel; Christophe Leclercq; Cecilia Linde; Joann Lindenfeld; Bela Merkely; Lluis Mont; Francis Murgatroyd; Frits Prinzen; Samir F Saba; Jerold S Shinbane; Jagmeet Singh; Anthony S Tang; Panos E Vardas; Bruce L Wilkoff; Jose Luis Zamorano
Journal:  Heart Rhythm       Date:  2012-09       Impact factor: 6.343

4.  Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group.

Authors:  A Auricchio; C Stellbrink; M Block; S Sack; J Vogt; P Bakker; H Klein; A Kramer; J Ding; R Salo; B Tockman; T Pochet; J Spinelli
Journal:  Circulation       Date:  1999-06-15       Impact factor: 29.690

5.  Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment.

Authors:  Marco Merlo; Stylianos A Pyxaras; Bruno Pinamonti; Giulia Barbati; Andrea Di Lenarda; Gianfranco Sinagra
Journal:  J Am Coll Cardiol       Date:  2011-03-29       Impact factor: 24.094

6.  Is "hyper response" to cardiac resynchronization therapy in patients with nonischemic cardiomyopathy a recovery, a remission, or a control?

Authors:  Philippe Castellant; Erwann Orhan; Valerie Bertault-Valls; Marjaneh Fatemi; Yves Etienne; Jean-Jacques Blanc
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-10       Impact factor: 1.468

7.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

8.  Device Longevity in a Contemporary Cohort of ICD/CRT-D Patients Undergoing Device Replacement.

Authors:  Francesco Zanon; Cristian Martignani; Ernesto Ammendola; Endrj Menardi; Maria Lucia Narducci; Paolo DE Filippo; Matteo Santamaria; Andrea Campana; Giuseppe Stabile; Domenico Rosario Potenza; Gianni Pastore; Matteo Iori; Concetto LA Rosa; Mauro Biffi
Journal:  J Cardiovasc Electrophysiol       Date:  2016-06-17

9.  Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.

Authors:  Cecilia Linde; William T Abraham; Michael R Gold; Martin St John Sutton; Stefano Ghio; Claude Daubert
Journal:  J Am Coll Cardiol       Date:  2008-11-07       Impact factor: 24.094

10.  Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer.

Authors:  Maurizio Landolina; Antonio Curnis; Giovanni Morani; Antonello Vado; Ernesto Ammendola; Antonio D'onofrio; Giuseppe Stabile; Martino Crosato; Barbara Petracci; Carlo Ceriotti; Luca Bontempi; Martina Morosato; Gian Paolo Ballari; Maurizio Gasparini
Journal:  Europace       Date:  2015-05-14       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.